Mini-GLP-1 Maintenance Dosing: The Long-Term Strategy Emerging From Data
The weight regain problem following GLP-1 receptor agonist discontinuation has become one of the most discussed challenges in obesity research. After the landmark STEP 1 trial extension showed that participants regained approximately two-thirds of lost weight within a year of stopping semaglutide, researchers and clinicians began asking a different question: what if the goal isn't maximum dose escalation, but finding the lowest effective maintenance dose?
A growing body of evidence suggests that reduced "mini-doses" of GLP-1 receptor agonists — doses well below the standard therapeutic maximum — may preserve metabolic benefits while minimizing side effects and cost. This approach is reshaping how long-term GLP-1 therapy is conceptualized.
The Rebound Problem That Started the Conversation
The data on post-cessation weight regain is striking. In the STEP 1 trial extension published by Wilding et al., 2022, participants who discontinued semaglutide 2.4 mg after 68 weeks regained 11.6 percentage points of body weight over the following year, retaining only about one-third of their initial loss.
Tirzepatide showed a similar pattern. The SURMOUNT-4 trial (Aronne et al., 2024) demonstrated that participants randomized to placebo after a 36-week lead-in period with tirzepatide regained approximately 14% of body weight over 52 weeks, compared to continued weight loss in those who stayed on the drug.
These findings confirmed what many suspected: GLP-1 receptor agonists treat obesity as a chronic condition, and discontinuation leads to physiological rebound. But they also raised urgent questions about sustainability — both metabolically and financially.
What Counts as a "Mini-Dose"?
There is no formal clinical definition of mini-dosing in the GLP-1 context, but the concept generally refers to maintenance dosing at levels significantly below the approved maximum therapeutic dose. For reference, the standard approved ranges are:
Mini-dose maintenance strategies typically involve stabilizing patients at doses like 0.25–0.5 mg of semaglutide or 2.5–5.0 mg of tirzepatide after initial weight loss has been achieved at higher doses. The hypothesis is that these lower doses may be sufficient to maintain the neurohormonal signaling that prevents weight regain without the full side effect burden.
Emerging Evidence for Lower Maintenance Doses
Several lines of evidence support the biological plausibility of mini-dose maintenance. The STEP 5 trial (Garvey et al., 2022) demonstrated that semaglutide 2.4 mg maintained weight loss over two full years, but notably, much of the metabolic benefit — improvements in insulin sensitivity, inflammatory markers, and appetite regulation — appeared to plateau well before the maximum dose was reached during initial titration.
A retrospective analysis by Ghusn et al., 2024 examined real-world outcomes in patients who reduced their semaglutide dose after achieving target weight loss. The findings suggested that a meaningful proportion of patients maintained ≥10% total body weight loss on reduced doses, although individual variability was significant.
The OASIS 1 trial (Knop et al., 202301185-6)) of oral semaglutide at 50 mg daily showed robust weight loss, but earlier dose-finding studies indicated that even lower oral doses produced measurable effects on appetite and glycemic control, pointing to a dose-response curve that may flatten at the maintenance phase.
From a mechanistic standpoint, the GLP-1 receptor system exhibits characteristics that could support lower maintenance dosing. Drucker, 2018 has extensively reviewed how GLP-1 receptor agonists modulate hypothalamic appetite circuits, vagal afferent signaling, and gastric emptying. Once these systems have been "reset" through a period of higher-dose therapy, it is plausible that less pharmacological input is required to sustain the new equilibrium.
The Dose-Response Curve Isn't Linear
One of the most important insights supporting mini-dose strategies is that GLP-1 receptor agonist dose-response curves are not strictly linear for all endpoints. The SUSTAIN dose-ranging studies for semaglutide (Pratley et al., 201830024-X)) showed that HbA1c reduction and weight loss both follow a curve of diminishing returns — the jump from 0.5 mg to 1.0 mg produces a larger incremental benefit than the jump from 1.0 mg to 2.0 mg.
This pattern suggests that lower doses capture a disproportionate share of the total pharmacological effect. For a patient who has already achieved significant weight loss, a dose that delivers 60–70% of the maximal receptor activation may be sufficient to prevent the hormonal cascade that drives regain.
Similarly, tirzepatide dose-finding data from the SURPASS program (Frías et al., 2021) showed meaningful glycemic and weight effects even at the 5 mg dose, though the 10 mg and 15 mg doses produced greater absolute weight loss. The question for maintenance is whether someone who has already lost weight needs the same pharmacological stimulus as someone beginning treatment.
Side Effect Reduction as a Practical Driver
Beyond the metabolic rationale, tolerability is a major factor pushing interest in mini-dose approaches. GLP-1 receptor agonist side effects are predominantly dose-dependent, with gastrointestinal complaints being the most common reason for discontinuation.
The STEP trials reported nausea rates of approximately 44% at the 2.4 mg semaglutide dose (Wilding et al., 2021), while lower doses during titration were substantially better tolerated. For long-term adherence — which is the single most important factor in maintenance — a dose that patients can sustain without significant GI distress has inherent advantages.
Real-world adherence data paints a sobering picture. An analysis of pharmacy claims data by Guar et al., 2024 found that a majority of patients discontinued GLP-1 receptor agonists within the first year, with side effects and cost being primary drivers. A lower maintenance dose addresses both concerns simultaneously.
What We Don't Know Yet
Despite the logical appeal, mini-dose maintenance strategies still lack definitive prospective trial data. Key unanswered questions include:
Several ongoing clinical trials are beginning to address these gaps, including studies evaluating dose de-escalation protocols after initial weight loss targets are met. The results of these trials, expected over the next two to three years, will likely reshape prescribing guidelines.
The Individualized Approach
What is becoming increasingly clear is that GLP-1 therapy is not a one-size-fits-all intervention, and the maximum approved dose may not be the optimal long-term dose for every individual. The emerging paradigm treats the weight loss phase and the maintenance phase as pharmacologically distinct, potentially requiring different dosing strategies.
This mirrors approaches in other areas of medicine — induction versus maintenance dosing is standard in immunology, psychiatry, and infectious disease. Obesity medicine may simply be catching up to this principle.